Search
Menu

Cytek Biosciences Closes Series D Funding with $120M

Facebook X LinkedIn Email
FREMONT, Calif., Nov. 5, 2020 — Cytek Biosciences announced the closing of a $120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. The investment will be used to expand Cytek’s global infrastructure and maintain growth. RA Capital and Hillhouse Capital have also joined Cytek’s board of directors.

“Cytek is ushering in flow cytometry’s next chapter with its proven, unique combination of innovative technologies,” said Andrew Levin, managing director of RA Capital. “We are excited to join them on their mission to advance cancer and cell biology research.”


Published: November 2020
Glossary
flow cytometry
Flow cytometry is a powerful technique used in biology and medicine for the quantitative analysis of the physical and chemical characteristics of cells and particles suspended in a fluid. The method allows for the rapid measurement of multiple parameters simultaneously on a cell-by-cell basis. It is widely used in various fields, including immunology, microbiology, hematology, and cancer research. Here are the key components and features of flow cytometry: Sample preparation: Cells or...
BusinessBiophotonicsfundingSeries D fundinginvestmentCytek Biosciencescapitalflow cytometryspectroscopycytometerflow cytometerflow cytometerscytometry

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.